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Abstract
Combretastatin-A4 disodium phosphate (CA4DP) is a
vascular-disruptive agent that causes an abrupt de-
crease in tumor blood flow. The direct actions of CA4DP
include increases in vascular permeability and destabi-
lization of the endothelial cytoskeleton, which are
thought to contribute to occlusion of the tumor vascu-
lature. It has been proposed that increased perme-
ability causes a transient increase in interstitial fluid
pressure (IFP), which in turn could collapse intra-
tumoral blood vessels. We examined the immediate
effects of CA4DP on tumor IFP in C3H mammary carci-
noma. Mice were treated with 100 mg/kg CA4DP by
intraperitoneal injection. Tumor perfusion was re-
corded by laser Doppler flowmetry at separate time
points, and IFP was recorded continuously by the wick-
in-needle method. In this study, we found that CA4DP
treatment resulted in a rapid reduction in tumor per-
fusion, followed by a decrease in IFP; no increases in
IFP were observed. This suggests that CA4DP-induced
reductions in tumor perfusion are not dependent on
increases in IFP.
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Introduction
Combretastatins are potent inhibitors of microtubule as-
sembly and are derivatives of the antineoplastic con-
stituent isolated from the plant Combretum caffrum [1].
These agents cause tumor blood flow disruption and sub-
sequent tumor cell death [2]. In particular, the water-soluble
combretastatin-A4 prodrug, combretastatin-A4 disodium
phosphate (CA4DP), has shown great clinical promise [3,4]
and is now under evaluation in phase II clinical trials [5].
In numerous studies, combretastatin-A4 has been
shown to have cytostatic and cytotoxic effects on prolifer-
ating tumor and endothelial cells (ECs) [6–10]. However,
the ability of CA4DP to cause abrupt vascular shutdown
in vivo at relatively nontoxic doses in a variety of tumors
[11] is much more remarkable. Due to the rapid onset of
vascular shutdown and the limited bioavailability of the drug
in vivo, the effects cannot be attributed to cytostatic or cyto-
toxic effects [12].
Treatment with CA4DP disrupts the tubulin cytoskeleton of
dividing ECs within a few minutes [13,14]. Many different
approaches have been employed to investigate how tubulin
depolymerization causes an abrupt shutdown of tumor vas-
culature. Numerous factors are thought to play a role in this
effect of CA4DP, including activation of the clotting system,
changes in red blood cell deformability and rouleaux forma-
tion, adherence of leukocytes to the endothelium, and vascular
constriction [15–17]. However, these mechanisms are not
sufficient to explain abrupt decreases in tumor perfusion, as
CA4DP causes only moderate vasoconstriction and retains an
effect on tumors perfused with solutions free of cells and
clotting factors [8,15,18,19].
The most important mechanisms are thought to involve
EC shape changes and increased vascular permeability
[12,18–20]. Several papers have suggested the principal
mechanism of vascular occlusion involving vascular col-
lapse caused by increases in interstitial fluid pressure (IFP)
[12,15,18,20]. However, none of these studies includes actual
measurements of IFP after CA4DP treatment. The only direct
measurement of tumor IFP presently known to the authors was
performed z 1 hour after CA4DP treatment [Kristjansen et al.
[4]3; Nielsen T, Murata R, Ley CD, Maxwell RJ, Kristjansen
PEG, Stodkilde-Jorgensen H, Overgaard J, Horsman MR. Fac-
tors of importance for the vascular effects of combretastatin
Abbreviations: CA4DP, combretastatin-A4 disodium phosphate; EC, endothelial cell; IFP,
interstitial fluid pressure; LDF, laser Doppler flowmetry; MVP, microvascular pressure; PU,
perfusion units
Address all correspondence to: Carsten D. Ley, MSc, The Edwin L. Steele Laboratory,
Massachusetts General Hospital/Harvard Medical School, 100 Blossom Street, Boston, MA
02114. E-mail: science@ley.dk
1This research was supported by grants from the Danish Cancer Society and the Danish
Medical Research Council.
2Conflict-of-interest statements: Carsten D. Ley: none; Michael R. Horsman: serves as con-
sultant for Oxigene, Inc., and assists with research programs determining certain relation-
ships between Oxigene’s drugs and radiation; Paul E. G. Kristjansen: none.
3A single dose of 250 mg/kg CA4DP was found to cause a significant decrease in IFP at
3 hours after treatment in C3H mouse mammary carcinoma (14.2 ± 1.3 mmHg compared to
a control level of 27.2 ± 2.6 mmHg; P = .003).
Received 15 November 2006; Revised 8 January 2007; Accepted 8 January 2007.
Copyright D 2007 Neoplasia Press, Inc. All rights reserved 1522-8002/07/$25.00
DOI 10.1593/neo.06733
Neoplasia . Vol. 9, No. 2, February 2007, pp. 108–112 108
www.neoplasia.com
BRIEF ARTICLE
A4 disodium phosphate (in preparation)4; Eikesdal et al. [22]],
which is later than the onset of effects such as hypoxia [23],
perfusion [24], and increased vascular resistance [18].
In this study, we investigate the time-dependent effects of
CA4DP on IFP and tumor perfusion with the aim of clarifying
the mode of action of combretastatins. C3H mammary carci-
noma was chosen as a model system because of the well-
characterized effects of CA4DP on this model: treatment
with CA4DP specifically reduces tumor perfusion at doses
well below the maximum tolerated dose, without causing
similar effects in normal tissues [25,26]. In addition, this
model has been shown to be amenable to accurate mea-
surements of the acute changes in tumor perfusion elicited
by vascular-targeting agents [24,27].
Materials and Methods
Animals and Tumors
A C3Hmammary carcinoma grown subcutaneously in the
right rear foot of 10- to 14-week-old female CDF1 mice was
used in this study. The derivation and maintenance of this
tumor have been described previously [28]. Tumor volume
was calculated from the formula: Vtumor = p/6[(d1  0.5)(d2 
0.5)]3/2, where d1 and d2 values represent two orthogonal
diameters [mm], and 0.5 mm is subtracted from each mea-
sured diameter to compensate for skin thickness. Experi-
ments were performed when tumors had reached a size of
approximately 250 to 350 mm3 (typically 3 weeks after
inoculation). C3H tumors of this size contain only little necro-
sis [25], are uniformly firm without ulcerations, and permit
normal use of the foot, but are big enough to accommodate
the needle for IFP measurements. The mice were kept in
standard housing conditions with free access to food and
water; lighting was controlled in a 12-hour light/dark cycle.
National and institutional guidelines for animal welfare and
experimental conduct were followed.
Drug Preparation
CA4DP was supplied by Oxigene, Inc. (Watertown, MA).
CA4DP was dissolved in isotonic normal saline at a con-
centration of 12.5 mg/ml such that injection of 0.2 ml corre-
sponded to a dose of 100 mg/kg in a 25-g mouse. A single
intraperitoneal injection of CA4DP at 100 mg/kg has been
shown to be nontoxic and to elicit changes in tumor perfusion
without significantly affecting tumor growth rates [11,25,29].
CA4DP solutions were stored in the dark at +4jC and
used within 1 week of preparation.
Laser Doppler Flowmetry (LDF) Perfusion Measurement
LDF was carried out using a setup with a Periflux Laser
Doppler flowmeter 4001 (Perimed, Stockholm, Sweden) and a
custom-built probe with four integrated laser/receiver units
(outer diameter, 6mm; fiber separation, 250 mm; timeconstant,
0.2 s; PF415-175; Perimed). Laser light at a wavelength of
780 nm was transmitted into the skin from the 42jC heated
probe. The probe was held steady in the desired position by
a micromanipulator. LDF signal was recorded continuously for
2 to 3 minutes while the calculated perfusion in arbitrary
perfusion units (PU) was monitored graphically. During re-
cording, care was taken to position the probe such that respi-
ratory movements did not influence the readings (this was
determined from the graphic representation of measured PU
values). As soon as steady state hadbeen reached (typically in
60–90 seconds), three individual values were noted from the
display. The median of these three values was used for further
data analysis. The LDF measurement apparatus was cali-
brated to 250 PU in a ‘‘motility standard’’ reference solution
(Perimed) before the measurements, and calibration was
regularly confirmed. Calibration was stable over time.
IFP Measurements
IFP was measured by the wick-in-needle technique [30],
with minor modifications [31]. A 23-gauge sensing needle
with a 2-mm side hole was inserted into the central part of
the tumor. The needle remained in the same position during
the entire experiment, ensuring that all time points would
be equally affected in case of spatial heterogeneity within
the tumor. The sensing needle was coupled to a pres-
sure sensor by a water column in a tubing (inner diameter,
0.58mm). This pressure sensor was connected to aMacLab/
4e digitizer (ADInstruments Ltd., Castle Hill, Australia)
through an ML112 bridge amplifier (ADInstruments Ltd.).
Pressure data from the sensor were collected from the
MacLab/4e digitizer using a PC with PowerLab Chart soft-
ware v. 4.2 (ADInstruments Ltd.). The pressure-sensing sys-
tem was calibrated against a water column of predefined
height before each experiment, and calibration stability was
confirmed at the end of each experiment. Calibration re-
mained stable over time.
General Experimental Design
All experiments were carried out in a temperature-
stabilized room at 25jC. Animals were anesthetized by a
subcutaneous injection of 0.3 ml of xylazine (Rompun;
Bayer Healthcare, Kgs. Lyngby, Denmark) and ketamine
(Ketalar; Pfizer, Sollentuna, Sweden) diluted 1:4:15 in iso-
tonic normal saline.
In initial experiments of 90 minutes’ duration, the drug
(saline for controls) was administered exactly 10 minutes
before anesthesia for the best possible vascular volume
equilibration after drug injection (before the anesthetic effect
sets in) and the longest possible duration of anesthesia.
Measurements were started 15 minutes after treatment.
LDF was measured at 15-minute intervals, and the IFP of
the same tumors was recorded continuously until the end
of the experiment.
To investigate acute effects within the first 15 minutes of
treatment, we conducted a second series of experiments. In
these experiments, anesthesia was administered exactly
30minutes before drug administration, and IFPwas recorded
4A single dose of 100 mg/kg CA4DP was found to significantly decrease IFP in tumors
sized f 300 mm3 and in f 800 mm3 of the highly sensitive KHT sarcoma. However, IFP
was decreased only in f 300-mm3 tumors of the C3H tumor line, and not in f 800-mm3
tumors. This seemed attributable to lower IFP levels in large untreated C3H tumors,
compared to the other untreated groups.
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continuously, from 10 minutes before treatment to 30 min-
utes after treatment. Animals were sacrificed at the end of
the experiments.
Statistical Analysis
Statistical significance was determined by two-tailed
Mann-Whitney U test, which was performed using SPSS
for Windows (SPSS Science, Chicago, IL). P < .05 was ac-
cepted as statistically significant.
Results
CA4DP Decreases Tumor Perfusion Measured By LDF
Perfusion was measured at 15-minute intervals, 15 to
90 minutes after CA4DP treatment. As shown in Figure 1,
tumor perfusion was reduced at all posttreatment time
points, following CA4DP treatment. In control mice, tumor
perfusion remained stable at around 105 arbitrary PU
throughout the experiment. The mean perfusion of treated
tumors had dropped to 59 PU at 30 minutes after treat-
ment (treated, n = 13; control, n = 9; P = .004), continued to
decrease until 60 minutes after treatment, and then re-
mained stable at around 37 PU. Prolonged measurements
of some of the CA4DP-treated tumors showed that this
stabilization in tumor perfusion persisted for at least 3 hours
after treatment (data not shown).
CA4DP Decreases Tumor IFP
Tumor IFP was measured at 15-minute intervals, 15 to
90 minutes after CA4DP treatment. Treated tumors had IFP
lower than that of control tumors at all time points (Figure 2).
By 45 minutes after treatment, IFP had been significantly
reduced to 72% of control levels (treated, n = 13; control,
n = 9; P = .043). No further IFP reductions were observed at
later time points. Three hours after treatment, IFP levels of
approximately 70% of controls have been observed (Nielsen
et al., unpublished observations), which indicates that IFP
does not recover within that period.
IFP measurements were normalized to control levels at
the relevant time point to highlight changes in IFP caused by
theCA4DP treatment. Temporal fluctuations in IFP and tumor
blood flow in treated and untreated tumors have been
observed by other investigators [15]. Anesthesia-induced
changes in heart rate and peripheral vasoconstriction can
cause modest elevations in IFP, as seen in both treated
and untreated animals at later experimental time points (ab-
solute IFP values from the experiment are shown in Table 1).
To evaluate acute (< 15 minutes posttreatment) changes
elicited by CA4DP, IFP was measured immediately after drug
administration in a second series of experiments (Figure 3).
IFP in treated tumors was significantly lower than that in
controls as early as 30 minutes after treatment (treated,
n = 12; control, n = 9; P = .015). No increases in IFP were
observed. To illustrate even subtle effects of the drug aswell as
possible, results are shown as percent pretreatment IFP (the
shorter duration of these experiments permitted us to obtain
measurements of baseline IFP levels before treatment). Ab-
solute IFP values from this experiment are shown in Table 2.
Discussion
CA4DP has been shown to increase endothelial perme-
ability in an in vitro model of vasculature [18] and in tumor
Figure 1. LDF perfusion measurements after treatment with 100 mg/kg
CA4DP (mean ± SD). CA4DP significantly reduced tumor perfusion 30 min-
utes after treatment (treated, n = 13; control, n = 9; P = .004). Tumor perfu-
sion stabilized at around 37 PU at about 60 minutes after treatment.
Figure 2. Tumor IFP after treatment with 100 mg/kg CA4DP. For clarity,
measurements were normalized to the control level at the relevant time point;
error bars represent SD. IFP in the treated group is significantly decreased
from 45minutes after treatment onward (treated, n = 13; control, n = 9; P < .05).
Table 1. Absolute IFP Values (Mean ± SD) Measured 15 to 90 Minutes after
CA4DP Treatment.
Time after CA4DP (minutes) IFP (mmHg)
Control CA4DP
15 13.1 ± 2.8 12.3 ± 4.0
30 12.3 ± 2.9 10.0 ± 3.6
45 12.3 ± 3.3 8.9 ± 4.0
60 13.2 ± 5.3 9.2 ± 3.4
75 13.3 ± 3.2 9.3 ± 3.4
90 15.3 ± 5.1 9.2 ± 3.9
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vasculature in vivo [15]. Increasing vascular permeabilitymay
raise the hematocrit by augmenting the filtration of fluid and
macromolecules, primarily albumin. This would increase
blood viscosity, possibly decreasing blood flow through the
tumor [15,18]. In addition, augmented extravasation could
raise the extravascular content of macromolecules, further
increasing hydrostatic pressure in tumor interstitial spaces,
which in turn may increase IFP. Several authors propose
that increased endothelial permeability might be the primary
event in the action of CA4DP, increasing blood viscosity and
transiently elevating IFP to an extent that could collapse—
and thus occlude—tumor blood vessels [12,15,18,20].
Alternatively, it has been suggested that EC shape
changes are, in fact, the primary event in reducing tumor per-
fusion, as the rounding up and protrusion of ECs into the vas-
cular lumen may lead to obstruction. Rounding might also
promote intratumoral thrombus formation due to contact
between blood and the basal lamina, as well as EC detach-
ment. EC shape changes occur with a similar time course
as the in vivo effects of CA4DP on tumor blood flow, implying
that they may be a key component of the mechanism
[5,8,9,13,14]. Intravascular clotting, vessel obstruction, or
both would cause a rapid decrease in perfusion. Interruption
of blood supply would decrease microvascular pressure
(MVP) inside large parts of the tumor vasculature, removing
the source of fluid for filtration across the vascular mem-
brane. As MVP is the principal driving force of IFP [31], IFP
would drop in a rate defined by the diffusion of fluid out of
the tumor periphery and other functional tumor drainage.
We found tumor perfusion to be significantly decreased
by as early as 30 minutes posttreatment, thus confirming
that CA4DP works as a vascular-disruptive agent in the C3H
mammary carcinoma. This is in good agreement with pre-
vious studies of tumor perfusion (Kragh et al. [24]; Eikesdal
et al. [32]; Kristjansen et al., [21]) and measurements of red
blood cell velocity [15] after CA4DP treatment. In our initial
IFP measurements, no increases in IFP were observed at 15
minutes posttreatment or later. On the contrary, IFP was
significantly reduced compared to control levels at 45minutes
posttreatment and beyond. This indicates that the effect of
CA4DP on tumor perfusion precedes significant modulation
of IFP. These findings do not support the concept that
vascular collapse is caused by IFP increases; however, a
transient short-term elevation of IFP in the first 15 minutes
after treatment cannot be excluded. We addressed this
possibility with a short-term IFP experiment, in which IFP
was monitored before treatment and immediately after.
Again, no increases in IFP were detected. Therefore, de-
creased perfusion after CA4DP treatment must be caused by
a different primary event, such as the EC shape changes
described above. The effects of CA4DP on permeability, as
demonstrated by other researchers [15], might not influence
tumor IFP significantly because: 1) blood and interstitial
space may be largely equilibrated beforehand as the tumor
endothelium is already leaky; or 2) the increase in perme-
ability is preceded or accompanied by a decrease in MVP.
Our failure to detect elevations in IFP after CA4DP treat-
ment is consistent with the findings of Eikesdahl et al. [22],
who did not detect changes in IFP. Perfusion was not as-
sessed in that particular study, but the authors have pre-
viously reported decreased perfusion after treatment with
CA4DP in the same experimental model [33]. Thus, CA4DP
did have an effect on perfusion in that setting, and this effect
was independent of any increase in IFP. We propose that the
large size of the tumors in the study (3.8–19 cm3) may be the
reason why IFP did not decrease after CA4DP treatment as it
did in other experimental models; similarly, IFP decreases
were not detected in very large C3H tumors treated with
CA4DP (Nielsen et al., unpublished observations).
The effects of CA4DP and the more potent derivative
AC7700 appear to differ in some aspects, but we consider
the finding that AC7700 immediately and markedly de-
creased IFP [34] to be further evidence against the con-
cept that combretastatins and their derivatives cause
vascular collapse by modulating vascular permeability, thus
increasing IFP.
In conclusion, we propose that reduced tumor perfusion
after CA4DP treatment of the C3H mammary carcinoma
Figure 3. Continuous IFP measurements after CA4DP treatment (100 mg/
kg), shown as percent pretreatment level (error bars represent SD; they were
omitted at time points 1, 2, 3, and 4 minutes for clarity). Treated IFP is not
significantly increased at any time point but is significantly decreased from
30 minutes after treatment onward (treated, n = 12; control, n = 9; P < .05).
Table 2. Absolute IFP Values (Mean ± SD) Measured before Treatment and
Until 30 Minutes after CA4DP Treatment.
Time after CA4DP (minutes) IFP (mmHg)
Control CA4DP
Pretreatment 16.3 ± 4.9 14.0 ± 4.8
1 15.5 ± 3.4 14.0 ± 4.1
2 15.6 ± 4.1 14.0 ± 4.7
3 15.1 ± 4.4 13.8 ± 5.0
4 15.8 ± 5.7 14.4 ± 6.1
5 15.5 ± 5.1 13.9 ± 5.5
10 16.7 ± 4.3 13.3 ± 5.4
15 15.5 ± 4.1 12.1 ± 4.8
20 15.6 ± 3.5 11.3 ± 4.7
25 15.7 ± 3.6 10.9 ± 4.7
30 15.7 ± 3.3 10.7 ± 4.8
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cannot be a consequence of vascular collapse caused by
high IFP, as treatment decreased perfusion even in the
absence of significant elevations in IFP. Our observation of
significant reductions in IFP indicates that CA4DP decreases
tumor perfusion by a mechanism that does not depend on
increases in IFP.
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